To include your compound in the COVID-19 Resource Center, submit it here.

Origins of metastasis in breast cancer

Researchers at the Albert Einstein College of Medicine of Yeshiva University and the Centocor Ortho Biotech Inc. unit of Johnson & Johnson have linked multiple prometastatic processes in breast cancer to the production of the chemokineCCL2 in tumor cells.1 The findings could aid the development of new therapeutics to prevent breast cancer metastasis, the main cause of breast cancer mortality in Western women,2 and could point to a new indication for the company's CNTO 888.

CNTO 888, an antibody against human monocyte chemoattractant protein-1 (MCP-1; CCL2), is in Phase II testing to treat metastatic, castration-resistantprostate cancer and Phase I trials for solid tumors. The compound also is in Phase II testing to treat idiopathic pulmonary fibrosis.3

CCL2 signals through CC chemokine receptor 2 (CCR2;

Read the full 1226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers